Sustained systemic delivery of monoclonal antibodies by genetically modified skin fibroblasts

Journal of Investigative Dermatology

Volumn 115, Issue 4, 2000, Pages 740-745

  Noël, Danièle ^a,c   Pelegrin, Mireia ^a   Brockly, Frédérique ^a   Lund, Anders H ^a,b   Piechaczyk, Marc ^a  

^a CNRS   (France)

^b AARHUS UNIVERSITY   (Denmark)

^c INSERM   (France)

Author keywords

Gene therapy; Immunotherapy; Monoclonal antibody; Skin fibroblasts

Indexed keywords

IMMUNOGLOBULIN; MONOCLONAL ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EXPRESSION VECTOR; GENE EXPRESSION; GENE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; SKIN FIBROBLAST; SUSTAINED RELEASE PREPARATION;

EID: 0033778745     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2000.00106.x     Document Type: Article

References (32)

1. The antibody response in HIV-1 infection
2. Immunoglobulins: Structure and function
3. High-titer packaging cells producing recombinant retroviruses resistant to human serum
4. Development of cellulose sulfate-based polyelectrolyte complex microcapsules for medical applications
5. Idiotypic restriction of murine monoclonal antibodies to a defined antigenic region of human thyroglobulin
6. The antiglobulin response to therapeutic antibodies
7. Increased clearance of IgG in mice that lack beta 2-microglobulin: Possible protective role of FcRn
8. In vivo delivery of recombinant human growth hormone from genetically engineered human fibroblasts implanted within Baxter immunoisolation devices
9. Cell targeting by murine retroviral vectors
10. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?
11. Mutated primer binding sites interacting with different tRNAs allow efficient murine leukemia virus replication
12. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease
13. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
14. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production
15. Retroviral vectors containing putative internal ribosome entry sites: Development of a polycistronic gene transfer system and application to human gene therapy
16. Continuous systemic secretion of a lysosomal enzyme by genetically modified mouse skin fibroblasts
17. Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts
18. Long-term delivery of a lysosomal enzyme by genetically modified fibroblasts in dogs
19. Sustained delivery of erythropoietin in mice by genetically modified skin fibroblasts
20. Analysis of the individual contributions of immunoglobulin heavy and light chains to the binding of antigen using cell transfection and plasmon resonance analysis
21. In vitro and in vivo secretion of cloned antibodies by genetically modified myogenic cells
22. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes
23. Systemic long-term delivery of antibodies in immunocompetent animals using cellulose sulphate capsules containing antibody-producing cells
24. In vivo production of therapeutic antibodies by engineered cells for immunotherapy of cancer and viral diseases
25. Production and characterization of monoclonal antibodies against human thyroglobulin
26. In vivo delivery of human α-L-iduronidase in mice implanted with neo-organs
27. Long-term expression of retrovirus-mediated gene transfer in mouse fibroblast implants
28. Antibody-based immunological therapies
29. Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of β-glucuronidase
30. The half-lives of serum immunoglobulins in adult mice
31. Monoclonal antibodies as agonists: An expanded role for their use in cancer therapy